These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 33602684

  • 21. Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
    Sartor C, Arpinati M, Chirumbolo G, Dozza L, Cristiano G, Nanni J, Marconi G, Robustelli V, Vigliotta I, Parisi S, Terragna C, Testoni N, Paolini S, Martinelli G, Curti A, Cavo M, Papayannidis C.
    Hematol Oncol; 2022 Oct; 40(4):734-742. PubMed ID: 35618655
    [Abstract] [Full Text] [Related]

  • 22. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
    Brivio E, Locatelli F, Lopez-Yurda M, Malone A, Díaz-de-Heredia C, Bielorai B, Rossig C, van der Velden VHJ, Ammerlaan ACJ, Thano A, van der Sluis IM, den Boer ML, Chen Y, Sleight B, Brethon B, Nysom K, Sramkova L, Øra I, Vinti L, Chen-Santel C, Zwaan CM.
    Blood; 2021 Mar 25; 137(12):1582-1590. PubMed ID: 33067614
    [Abstract] [Full Text] [Related]

  • 23. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment.
    Marks DI, van Oostrum I, Mueller S, Welch V, Vandendries E, Loberiza FR, Böhme S, Su Y, Stelljes M, Kantarjian HM.
    Cancer Med; 2019 Oct 25; 8(13):5959-5968. PubMed ID: 31436395
    [Abstract] [Full Text] [Related]

  • 24. Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.
    Stelljes M, Advani AS, DeAngelo DJ, Wang T, Neuhof A, Vandendries E, Kantarjian H, Jabbour E.
    Clin Lymphoma Myeloma Leuk; 2022 Sep 25; 22(9):e836-e843. PubMed ID: 35643855
    [Abstract] [Full Text] [Related]

  • 25. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
    Nakayama H, Ogawa C, Sekimizu M, Fujisaki H, Kosaka Y, Hashimoto H, Saito AM, Horibe K.
    Int J Hematol; 2022 Oct 25; 116(4):612-621. PubMed ID: 35635686
    [Abstract] [Full Text] [Related]

  • 26. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H.
    JAMA Oncol; 2018 Feb 01; 4(2):230-234. PubMed ID: 28859185
    [Abstract] [Full Text] [Related]

  • 27. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I, Su Y, Fahrbach K, Vandendries E, Pagé V, Onyekwere U, Wang Y, Cappelleri JC, Stelljes M.
    Adv Ther; 2019 Aug 01; 36(8):2147-2160. PubMed ID: 31140123
    [Abstract] [Full Text] [Related]

  • 28. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
    Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E.
    Clin Lymphoma Myeloma Leuk; 2020 Aug 01; 20(8):556-560.e2. PubMed ID: 32291234
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin.
    Reinert J, Beitzen-Heineke A, Wethmar K, Stelljes M, Fiedler W, Schwartz S.
    Ann Hematol; 2021 Nov 01; 100(11):2727-2732. PubMed ID: 34331563
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM.
    Cancer; 2018 Oct 15; 124(20):4044-4055. PubMed ID: 30307611
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
    Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM.
    Cancer; 2018 Apr 15; 124(8):1722-1732. PubMed ID: 29381191
    [Abstract] [Full Text] [Related]

  • 37. [Relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia responding to retreatment with inotuzumab ozogamicin].
    Hashimoto H, Tamura Y, Yamada K, Katoh Y, Shimada T, Fujiwara R, Hanamoto H.
    Rinsho Ketsueki; 2023 Apr 15; 64(8):746-750. PubMed ID: 37673626
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Dahl J, Marx K, Jabbour E.
    Expert Rev Hematol; 2016 Apr 15; 9(4):329-34. PubMed ID: 26783163
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.